相关实验视频

Updated: Jan 9, 2026

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization

Published on: December 2, 2013

使用链毒素的化学栓塞与转移性NET中的栓塞相比

Anne-Laure Védie¹, Francesco Matteini^2,3, Jérôme Cros⁴

¹Université Paris-Cité, Department of Pancreatology and Digestive Oncology, Beaujon Hospital (APHP.Nord), Clichy, France.

Endocrine-related cancer

|December 3, 2025

概括

在肝转移的神经内分泌瘤中,用条毒素 (STZ) 进行的跨动脉化学栓塞 (TACE) 显示出比跨动脉栓塞 (TAE) 更高的响应率. 低基氨酸-DNA-N-葡萄糖酶 (APNG) 表达可能预测TACE的疗效.

科学领域:

在瘤学瘤学.
干预性放射学干预性放射学

背景情况:

地方区域疗法是肝转移的神经内分泌瘤 (NET) 的标准.
通过动脉化学栓塞 (TACE) 与链毒素 (STZ) 与通过动脉栓塞 (TAE) 和预测生物标志物的疗效尚未得到充分研究.

研究的目的:

为了比较TACE-STZ与TAE在患有胰腺 (panNET) 或小肠 (siNET) NET和肝脏转移的患者中的疗效.
为了探索TACE-STZ疗效的预测生物标志物.

主要方法:

在2006-2022年间接受TACE-STZ或TAE治疗的116名患者的回顾性研究.
每个RECIST 1.1的目标响应率 (ORR) 是主要的终点.
评估了倾向性评分分析和瘤生物标志物表达 (MGMT,APNG,CAIX).

主要成果:

TACE-STZ的ORR (43%与22%相比,P=0.045) 显著高于TAE.
在panNET (12.9 vs 6.4个月,P=0.026) 中,TACE-STZ改善了无进展生存期 (PFS),但不是siNET患者.
较低的APNG表达预测TACE-STZ的ORR更高 (70%与16%,P<0.001).

结论:

在对具有肝转移的NET的响应率方面,TACE-STZ比TAE更有效.
TACE-STZ主要在泛网患者中提供PFS的好处.
低APNG表达可能会识别出可能从TACE-STZ治疗中受益的患者.

关键词:

生物标志物生物标志物肝脏转移的发生.神经内分泌瘤的神经内分泌瘤这种药物是链条毒素 (streptozotocin).通过动脉的化学栓塞.

更多相关视频

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients

Published on: September 20, 2020

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...